follow-up
Last reviewed 07/2021
- men with prostate cancer who have chosen a watchful waiting regimen with
no curative intent should normally be followed up in primary care in accordance
with protocols agreed by the local urological cancer MDT and the relevant
primary care organisation(s)
- their PSA should be measured at least once a year
- their PSA should be measured at least once a year
- if patient had radical treatment
- check PSA levels for all men with prostate cancer who are having
radical treatment at the earliest 6 weeks following treatment, at least
every 6 months for the first 2 years and then at least once a year thereafter
- check PSA levels for all men with prostate cancer who are having
radical treatment at the earliest 6 weeks following treatment, at least
every 6 months for the first 2 years and then at least once a year thereafter
- do not routinely offer DRE to men with localised prostate cancer while the
PSA remains at baseline levels
- after at least 2 years
- offer follow-up outside hospital (for example, in primary care) by telephone
or secure electronic communications to men with a stable PSA who have
had no significant treatment complications, unless they are taking part
in a clinical trial that requires formal clinicbased follow-up
- direct access to the urological cancer MDT should be offered and explained
- offer follow-up outside hospital (for example, in primary care) by telephone
or secure electronic communications to men with a stable PSA who have
had no significant treatment complications, unless they are taking part
in a clinical trial that requires formal clinicbased follow-up
Reference:
watch and wait in prostatic cancer
PSA guidance for primary care relating to follow - up after diagnosis of prostate cancer